Figure 4.

The efficacies of chemotherapy for chemo-naive patients and osimertinib for patients with both BRAF variants and T790M after failure of previous EGFR TKIs. Chemo is shown by the green bar; the chemo-regimens are indicated. Osimertinib is indicated by the blue bar. ∗These two patients experienced disease progression after 1 month and BRAF fusions were subsequently detected. Chemo, chemotherapy; NGS, next-generation sequencing; P, patient; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.